OR WAIT null SECS
May 03, 2021
This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.
Both the European Commission and FDA have granted approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating endometrial cancer.
Applying a QbD approach helps address excipient variability and other quality features.
April 26, 2021
Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.
April 22, 2021
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
Topical drugs are attractive to patients, but these complex products pose challenges for formulators.
March 22, 2021
The companies will work to discover and develop RNA-targeting small-molecule therapeutics for difficult-to-address indications.
March 15, 2021
Continuus Pharmaceuticals is building the first GMP facility using integrated continuous manufacturing technology for end-to-end production of small-molecule APIs and finished dosage forms.
March 08, 2021
USP is collaborating with Phlow to build a new lab that will develop test methods and standards to facilitate broader adoption of continuous manufacturing.